There are now 12 classes of antihyperglycemic medications available for patients with type 2 diabetes mellitus (DM). With an estimated 30 million patients in the United States living with DM1 and increasing complexity and financial burden of DM care, the relative distribution of expenditures across DM therapeutic classes needs to be reexamined. We evaluated trends in aggregate use and expenditures for all DM therapies among US Medicare Part D beneficiaries from 2012 to 2017.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sumarsono A, Everett BM, McGuire DK, et al. Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. JAMA Intern Med. 2020;180(1):141–144. doi:10.1001/jamainternmed.2019.3884
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: